Primary systemic therapy of breast cancer.

  title={Primary systemic therapy of breast cancer.},
  author={Irina Sachelarie and Michael L. Grossbard and Manjeet Chadha and Sheldon Feldman and Munir Ghesani and Ronald H. Blum},
  journal={The oncologist},
  volume={11 6},
Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The multitude of clinical trials using PST in breast cancer patients has not proven the fundamental hypotheses of improved overall survival and disease-free survival that drove the investigation of PST. The other potential advantages of PST, which include increasing… 

Tables from this paper

Neoadjuvant Treatment with Paclitaxel and Epirubicin in Invasive Breast Cancer

Treatment with a combination of epirubicin and paclitaxel enabled lumpectomy in a substantial proportion of women who were previously deemed to not be suitable candidates for breast-conserving surgery.

Neoadjuvant systemic treatment of breast cancer

The biological underpinnings of the different types of breast cancer in order to design better treatments that will ultimately improve the eradication rate of this disease are understood.

Preoperative chemo- and endocrine therapy.

  • R. Torrisi
  • Medicine
    Cancer treatment and research
  • 2009
A number of randomised trials comparing PST with postoperative administration of systemic treatment (adjuvant therapy) were designed in the 1990s, showing that, albeit a high objective response rate and a relevant proportion of patients, all these trials were consistent in showing that.

Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice

HR negativity, mastectomy and pathological stage III disease are the variables independently associated with a worse outcome in a cohort of patients treated with neoadjuvant systemic chemotherapy in routine clinical practice.

The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer.

Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions.

There are several advantages of administering primary systemic therapy (PST) instead of adjuvant therapy in the management of early breast cancer patients: (a) PST allows for a quantifiable

Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

The pCR rate following neoadjuvant chemotherapy for breast cancer in Thai women attending the authors' institution was 11.7%; pCR was more frequently observed in HER2 and triple-negative breast tumor subtypes.

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients

NPLD-cyclophosphamide and taxanes sequential regimens were proven effective and well tolerated in breast cancer patients with contra-indication to conventional anthracyclines undergoing neoadjuvant chemotherapy, even outside of clinical trials in everyday clinical practice.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  • C. LiedtkeC. Mazouni L. Pusztai
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
Patients with TNBC have increased pCR rates compared with non-TNBC, and those with pCR have excellent survival, however, patients with RD after neoadjuvant chemotherapy have significantly worse survival if they have TNBC compared with other patients, particularly in the first 3 years.

Locally advanced breast cancer

It remains to define better the role of endocrine therapy as PST, but it is acceptable in elderly women and, in all resource settings, should be standard treatment for inoperable breast cancer and for LABC.



Neoadjuvant Docetaxel in Locally Advanced Breast Cancer

The addition of docetaxel improved overall survival and disease-free survival for patients responding to four cycles of CVAP as compared with those receiving eight cycles ofCVAP and data from the NSABP B-27 and GEPAR-duo trials strongly support a combined anthracycline/docetaxe regimen in the neoadjuvant setting.

Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.

The addition of sequential docetaxel (100 mg/m2) to CVAP neoadjuvant chemotherapy resulted in a significantly enhanced clinical response rate and a substantially increased complete histopathological response rate when compared to patients receiving CVAP alone.

The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer.

NAHT with aromatase inhibitors (anastrazole) is a reasonable alternative to CT for PM women with ER and/or PgR - positive cancer in clinical situation where the low toxicity of the regimen is considered an advantage, for example, for women over 70.

Combined sequential approach in locally advanced breast cancer.

A multivariate analysis demonstrated a significant favorable prognosis in patients with limited nodal involvement at surgery and negative Mib-1 values and this drug sequence failed to significantly ameliorate the long term results in this unfavorable patient subset.

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

Neoadjuvant chemotherapy has the capacity to completely clear the breast and axillary lymph nodes of invasive tumor before surgery and patients with LABC who have a pCR in the breastand axillary nodes have a significantly improved disease-free survival rate.

Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy

The quality of response to induction chemotherapy correlated prominently with prognosis, as did compliance with treatment, and this multidisciplinary approach to locally advanced breast cancer rendered most patients disease‐free and produced an excellent local control rate.

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  • B. FisherJ. Bryant H. Bear
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
Preoperative chemotherapy is as effective as postoperative chemotherapy, permits more lumpectomies, is appropriate for the treatment of certain patients with stages I and II disease, and can be used to study breast cancer biology.

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.

  • A. MakrisT. Powles H. Ford
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 1998
A significant reduction in the surgical requirements for mastectomy, after treatment with neoadjuvant chemoendocrine therapy, with no deterioration in local or distal relapse is shown.

Feasibility of breast‐conservation surgery after induction chemotherapy for locally advanced breast carcinoma

The clinical, mammographic, and histologic responses were analyzed after three cycles of preoperative vincristine, doxorubicin, cyclophosphamide, and prednisone that were administered to 143 patients with locally advanced breast cancer.

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.

  • J. ChangT. Powles M. Dowsett
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
Molecular markers may be used to predict the likelihood of achieving GCR, which seems to be a valid surrogate marker for survival in patients with primary operable breast cancer who receive neoadjuvant therapy.